Cobicistat Patent Expiration

Cobicistat is Used for treating HIV infection by enhancing the pharmacokinetics and inhibiting cytochrome P450 monooxygenase. It was first introduced by Gilead Sciences Inc in its drug Tybost on Sep 24, 2014. 2 different companies have introduced drugs containing Cobicistat.


Cobicistat Patents

Given below is the list of patents protecting Cobicistat, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tybost US10039718

(Pediatric)

Use of solid carrier particles to improve the processability of a pharmaceutical agent Apr 06, 2033 Gilead Sciences Inc
Tybost US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent Oct 06, 2032 Gilead Sciences Inc
Tybost US8148374

(Pediatric)

Modulators of pharmacokinetic properties of therapeutics Mar 03, 2030 Gilead Sciences Inc
Tybost US8148374 Modulators of pharmacokinetic properties of therapeutics Sep 03, 2029 Gilead Sciences Inc



Cobicistat's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Cobicistat Generics

Only one generic application has been filed for Cobicistat.

Given below is the list of companies who have filed for Cobicistat generic.


1. MYLAN LABS LTD

Mylan Laboratories Ltd has filed for 1 generic for Cobicistat. Given below are the details of the strengths of this generic introduced by Mylan Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
150MG tablet Prescription ORAL AB Feb 7, 2024